INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.68 USD | +0.98% |
|
-1.28% | -17.69% |
| 04-24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
| 04-23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
| Sales 2024 * | 4.13B 330B | Sales 2025 * | 4.59B 367B | Capitalization | 11.6B 929B |
|---|---|---|---|---|---|
| Net income 2024 * | 797M 63.8B | Net income 2025 * | 991M 79.33B | EV / Sales 2024 * | 1.75 x |
| Net cash position 2024 * | 4.37B 350B | Net cash position 2025 * | 5.68B 454B | EV / Sales 2025 * | 1.29 x |
| P/E ratio 2024 * |
15.1
x | P/E ratio 2025 * |
11.9
x | Employees | 2,524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Incyte Corporation
More recommendations
More press releases
More news
| 1 day | +0.98% | ||
| 1 week | -1.28% | ||
| Current month | -9.29% | ||
| 1 month | -8.61% | ||
| 3 months | -14.78% | ||
| 6 months | -4.77% | ||
| Current year | -17.69% |
1 week
50.35
52.62
1 month
50.3557.40
Current year
50.3567.37
1 year
50.2775.74
3 years
50.2788.26
5 years
50.27110.37
10 years
43.44153.15
| Managers | Title | Age | Since |
|---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 12/01/14 |
| Director of Finance/CFO | 53 | 10/02/19 | |
Pablo Cagnoni
PSD | President | 60 | 04/06/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 31/12/00 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15/12/19 |
| Director/Board Member | 70 | 19/01/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.55% | 215 M€ | +10.68% | - | |
| 2.94% | 1 M€ | 0.00% | - | |
| 2.88% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 51.68 | +0.98% | 1,564,403 |
| 25/04/24 | 51.18 | -1.08% | 1,771,950 |
| 24/04/24 | 51.74 | +0.17% | 1,564,434 |
| 23/04/24 | 51.65 | -0.52% | 2,493,676 |
| 22/04/24 | 51.92 | -0.82% | 1,751,676 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
30/04/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
51.68
USD
Average target price
75.2
USD
Spread / Average Target
+45.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.69% | 11.49B | |
| -4.66% | 87.53B | |
| +1.32% | 40.42B | |
| -19.27% | 29.48B | |
| +57.86% | 25.43B | |
| -43.00% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B | |
| +2.29% | 7.67B |
- Stock Market
- Equities
- INCY Stock
